anti-glutamate carboxypeptidase (GCPII) iBody small molecule (tool compound)

An enzyme that in humans is encoded by FOLH1 (folate hydrolase 1)

Contributors

Inventor	Institute
Jan Konvalinka ; Jirí Schimer ; Tomas Knedlik ; Jan Tykvart ; Frantisek Sedlak ; Pavel Majer ; Vaclav Navratil ; Petr Cigler ; Vladimir Subr ; Karel Ulbich ; Jiri Stroham ; Pavel Sacha	Institute of Organic Chemistry and Biochemistry ; Institute of Macromolecular Chemistry ; Charles University

Cat. #:	157994
Tool sub type:	Marker
Research Fields:	Cell signaling and signal transduction;Other
Purpose:	Marker

Alternate name:	Glutamate Carboxypeptidase II, N-acetyl-L-aspartyl-L-glutamate peptidase I (NAALADase I), NAAG peptidase, prostate-specific membrane antigen (PSMA)
Product description:	An enzyme that in humans is encoded by FOLH1 (folate hydrolase 1). – iBodiesŽ are capable of replacing antibodies in biomedical applications such as ELISA, flow cytometry, confocal microscopy, immunocytochemistry, Western Blot and immunoprecipitation. – These iBodiesŽ consist of an N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer decorated with low-molecular-weight compounds that function as targeting ligand (e.g., enzyme inhibitors, receptor ligands), affinity anchor (e.g., biotin) and/o…
Additional notes:	HPMA conjugate characteristics: MW: 148 800g/mol #Biotins/molecule: 38 Fluorochrome name: ATTO488 #Fluorochrome/molecule: 7 iBodies(R) is a registered trade mark of IOCB Tech s.r.o.

Primary target:	Targeting human Glutamate Carboxypeptidase II (GPCII) using GPCII specific inhibitor

Shipping conditions:	Dry Ice

References:	Ĺ imon et al. 2018. ACS Chem Biol. 13(12):3333-3342. PMID: 30489064. DvoĹĂĄkovĂĄ et al. 2017. J Med Chem. 60(20):8385-8393. PMID: 28953383. Ĺ ĂĄcha et al. 2016. Angew Chem Int Ed Engl. 55(7):2356-60. PMID: 26749427.

Unfortunately this tool is not available through our online checkout process. Please contact our team directly to obtain further information on accessing this tool.

Enquire about this Tool

If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Request a license

Get technical support

New to CancerTools?

We are a trusted, non-profit platform for cancer research products, part of Cancer Research UK – by sourcing your cancer research tools from us you help fund future cancer research.

Find out more

Related Tools for Small molecules

Cat. #

Tool Name

151711

MGMT inhibitor Lomeguatrib Small Molecule (Tool Compound)

Key Info

Cat. #:	151711
Sub-type:	Inhibitor
Availability:	Please enquire for quantities and pricing
Application:	Lomeguatrib (20 mg/kg/day for 5 days) combined with Temozolomide (100 mg/kg/day for 5 days) produces a substantial tumour growth delay: median tumour quintupling time is increased by 22 days without any significant increase in toxicity, while neither of the two drugs administrated along show any antitumor activity. Lomeguatrib inactivates ATase and enhances the anti-tumour effect of Temozolomide in A375M human melanoma xenografts model. Lomeguatrib, at a single dose of 20 mg/kg i.p., produces…

View Tool

151712

CDK7 inhibitor BS-181 Small Molecule (Tool Compound)

Key Info

Cat. #:	151712
Sub-type:	Inhibitor
Availability:	Please enquire for quantities and pricing
Application:	BS-181 is stable in vivo with a plasma elimination half-life in mice of 405 minutes after i.p. administration of 10 mg/kg. BS-181 inhibits the growth of MCF-7 xenografts in the nude mice model in a dose-dependent manner, with 25% and 50% reduction in tumor growth after 2 weeks of treatment at 10 mg/kg/day and 20 mg/kg/day, respectively without apparent toxicity. BS-181 is a small molecule inhibitor of CDK7 in a cell-free environment, which displays more potential activity than roscovitine with IC 50 of 510 nM. Among the CDKs and other 69 kinases from many different classes, BS-181 shows high inhibitory selectivity for CDK7, inhibits CDK2 at concentrations lower than 1 ÎźM which being inhibited 35-fold less potently (IC50 with 880 nM) than CDK7, shows slight inhibition for CDK1, CDK4, CDK5, CDK6 and CDK9 with IC50 values higher than 3.0 ÎźM, and only shows inhibition for several kinases from other classes at high concentrations (>10 ÎźM). BS-181 promotes cell cycle arrest and inhibits the cancer cell growth of a range of tumor types, including breast, lung, prostate and colorectal cancer with IC50 in the range of 11.5-37 ÎźM. In MCF-7 cells, BS-181 inhibits the phosphorylation of the CDK7 substrate RNA polymerase II COOH-terminal domain (CTD), and promotes cell cycle arrest and apoptosis to inhibit the growth of cancer cell lines.

View Tool

151839

Antitumoral Phortress Small Molecule (Tool Compound)

Key Info

Cat. #:	151839
Sub-type:	Antitumoral
Availability:	Please enquire for quantities and pricing
Application:	Active against breast, ovarian and renal carcinomas. Taken up into sensitive cells followed by aryl hydrocarbon receptor binding and translocation into the nucleus. Requires metabolic activation by cytochrome P450 to generate cytotoxic species. Induces expression of CYP1A1 and generates adducts in the DNA of sensitive MCF7 and IGROV-1 cells.

View Tool

152754

CDK2 inhibitor NU6301 Small Molecule (Tool Compound)

Key Info

Cat. #:	152754
Sub-type:	Inhibitor
Availability:	Please enquire for quantities and pricing
Application:	The prodrug NU6301 rapidly generated NU6102 in vitro in mouse plasma, and tumour NU6102 levels in vivo consistent with activity in vitro. Eight or 12 hourly dosing of 120 mg/kg NU6301 for 10 days was well tolerated in SKUT-1B tumour-bearing mice and inhibited Rb phosphorylation in tumour tissue. Two (8 hourly dosing) and 3 (12 hourly dosing) day tumour growth delay was observed (p=0.04 and p=0.007, respectively) following NU6301 administration. NU6102 selectively inhibited the growth of CDK2 WT (wild type) versus KO MEFs (knockout mouse embryo fibroblasts) (GIââ (concentration required to inhibit cell growth by 50%) 14 ÎźM versus >30 ÎźM), and was more growth-inhibitory in p53 mutant or null versus p53 WT cells (p=0.02), and in Rb (retinoblastoma protein) WT SKUT-1B versus SKUT 1 Rb deficient cells (p=0.01). In SKUT-1B cells NU6102 induced a G2 arrest, inhibition of Rb phosphorylation and cytotoxicity (LCââ 2.6 ÎźM for a 24h exposure).

View Tool

152785

Mitochondrial Luminophore Small Molecule (Tool Compound)

Key Info

Cat. #:	152785
Sub-type:	Luminophore
Availability:	Please enquire for quantities and pricing

View Tool

By Category

By Cancer Type

More

anti-glutamate carboxypeptidase (GCPII) iBody small molecule (tool compound)

Contributors

Related Tools for Small molecules

Tool enquiry